New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.

A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

Exelixis (EXEL) is back in focus after reporting positive phase 3 results for its cancer drug zanzalintinib in metastatic ...

Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in ...

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...

MERCK is in talks to buy cancer drug developer Revolution Medicines in a $28-billion to $32-billion deal, the Financial Times ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a deal that may be worth $28 billion to $32 billion ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...